Edition:
India

GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

42.56USD
18 Oct 2019
Change (% chg)

$0.09 (+0.21%)
Prev Close
$42.47
Open
$42.52
Day's High
$42.61
Day's Low
$42.51
Volume
91,787
Avg. Vol
465,198
52-wk High
$43.22
52-wk Low
$36.42

Select another date:

Wed, Oct 9 2019

Photo

GSK recalls popular heartburn drug Zantac globally after cancer scare

GlaxoSmithKline on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the U.S. Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug. | Video

UPDATE 3-GSK recalls popular heartburn drug Zantac globally after cancer scare

* GSK recalls Zantac products in all markets as a "precaution"

GSK recalls popular heartburn medicine Zantac - U.K. medicines watchdog

Oct 8 GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a "precautionary measure" due to a probable cancer-causing impurity in the drug, Britain's medicines watchdog said on Tuesday.

Vectura, Sandoz win ruling on inhaler packaging case against GSK

Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

GlaxoSmithKline's cancer therapy cuts risk of disease progression or death by 38%

GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38% in a late-stage study in cancer patients.

GlaxoSmithKline's cancer therapy cuts risk of disease progression or death by 38%

Sept 30 GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38% in a late-stage study in cancer patients.

Results of GSK and AstraZeneca trials may widen ovarian cancer drug use

BARCELONA GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.

Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use

BARCELONA, Sept 28 GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.

GSK, AstraZeneca rivalry takes center stage at cancer conference

GlaxoSmithKline and AstraZeneca will each present trial data on a promising new class of drugs against ovarian cancer on Saturday as Britain's top drugmakers compete to burnish their oncology credentials.

GSK, AstraZeneca rivalry takes centre stage at cancer conference

Sept 26 GlaxoSmithKline and AstraZeneca will each present trial data on a promising new class of drugs against ovarian cancer on Saturday as Britain's top drugmakers compete to burnish their oncology credentials.

Select another date: